{
    "id": "0762",
    "question": "A 57-year-old man presents to his primary care physician for follow-up of his diabetes. He was diagnosed with type 2 diabetes 3 months ago and has been started on metformin and lifestyle modifications. The patient does not have any current complaints except for occasional numbness in both hands and feet. His HbA1C is 8.5% and serum glucose is 240 mg/dL. Which of the following is the best next step in this patient\u2019s condition?",
    "options": {
        "A": "Start basal-bolus insulin",
        "B": "Continue metformin monotherapy",
        "C": "Add a sulfonylurea",
        "D": "Add a thiazolidinedione"
    },
    "answer": "C",
    "predict": "{\"step_by_step_thinking\": \"To determine the best next step in this patient's condition, we need to consider his current HbA1C and serum glucose levels, as well as his symptoms and medication history. First, the patient's HbA1C of 8.5% and serum glucose of 240 mg/dL indicate that his diabetes is not well-controlled. The American Diabetes Association (ADA) recommends an HbA1C goal of less than 7% for patients with type 2 diabetes. The patient has been taking metformin for 3 months, which is a good starting point for type 2 diabetes management. However, given his poor glycemic control, it may be necessary to add additional therapy to improve his blood sugar levels. Considering his symptoms of numbness in both hands and feet, it is possible that his diabetes is causing nerve damage (neuropathy). This is a common complication of diabetes and can be managed with proper medication and lifestyle changes. The options provided are: A. Start basal-bolus insulin: This is a reasonable option for patients with type 2 diabetes who have poor glycemic control and are experiencing symptoms of neuropathy. Basal-bolus insulin therapy can help regulate blood sugar levels and provide more precise control. B. Continue metformin monotherapy: While metformin is a good first-line medication for type 2 diabetes, continuing monotherapy alone may not be sufficient for this patient given his poor glycemic control. C. Add a sulfonylurea: Sulfonylureas can stimulate insulin release from the pancreas, but they may not be the best choice for this patient due to their potential side effects and the risk of hypoglycemia. D. Add a thiazolidinedione: Thiazolidinediones can improve insulin sensitivity, but they may not be the best choice for this patient due to their potential side effects and the availability of other options. Given the patient's symptoms and poor glycemic control, starting basal-bolus insulin therapy is the most appropriate next step.\", \"answer_choice\": \"A\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 30.944889307022095
}